ArticleCancer research2017
An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Metabolic vulnerabilities in pleural mesothelioma.Oncogenesis · 2026Review
- Lipidomic profile of meningiomas harboring different NF2 mutation status.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Targeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma.Cell death & disease · 2026Article
- Processes and therapeutic perspectives of acylation modifications of lysine and cysteine in tumors.Cell communication and signaling : CCS · 2026Review
- Lysine malonylation as a therapeutic target: implications for metabolic, inflammatory, and oncological disorders.Amino acids · 2025Review
- De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.EMBO molecular medicine · 2025Article
- Acylcarnitine Profiling in Meningiomas with Different NF2 Mutation Statuses.International journal of molecular sciences · 2025Article
- NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.NPJ precision oncology · 2024Review
- G6PD and ACSL3 are synthetic lethal partners of NF2 in Schwann cells.Nature communications · 2024Article
- NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.International journal of molecular sciences · 2024Review
- High-throughput RNA sequencing identifies the miRNA expression profile, target genes, and molecular pathways contributing to growth of sporadic vestibular schwannomas.Acta neurochirurgica · 2024Article
- Lysine Malonylation and Its Links to Metabolism and Diseases.Aging and disease · 2023Review
- Preclinical Models of Meningioma.Advances in experimental medicine and biology · 2023Review
- Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma.BMC cancer · 2022Article
- UHPLC-HRMS-based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer.Frontiers in oncology · 2022Article
- An update on the CNS manifestations of neurofibromatosis type 2.Acta neuropathologica · 2020Review
- Review
- Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival.The Journal of biological chemistry · 2019Article
- Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Molecular and translational advances in meningiomas.Neuro-oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple tumors in the central nervous system, most notably schwannomas, and meningiomas. Mutational inactivation of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.